2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Gene Editing, Treatment Considerations, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Immunology, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

2999 Multi-omic profiling identifies ARHGAP31 as a direct ETV6 target and candidate driver of ETV6 P214L-induced thrombocytopenia

Hyder Mir, PhD, Post Doctoral Research Associate, Jesse Rowley, PhD2, Lilian Antunes Heck, PhD3, Thomas J. Girard, PhD4, Wei Yang5, Abigail Ajanel, PhD6, Jorge Di Paola, MD7
1 Washington University in St Louis, St Louis, Missouri, United States
2 University of Utah, Salt Lake City, United States
3 Washington University in St Louis, St Louis, Missouri, United States
4 Washington University in St Louis, St Louis, Missouri, United States
5 Washington University in St Louis, St Louis, Missouri, United States
6 Washington University in St Louis, St Louis, Missouri, United States
7 Washington University in St Louis, St Louis, Missouri, United States

Background: Germline mutations in ETV6 are associated with immature megakaryocytes, thrombocytopenia, platelet defects and predisposition to hematological malignancies. The ETV6 P214L mutation located within the central domain, creates a nuclear export signal that results in the aberrant cytoplasmic localization of ETV6. This mislocalization is typical of the majority of pathogenic ETV6 missense variants, impairing transcriptional repression and disrupting hematopoiesis. Despite the essential role of ETV6 in hematopoiesis and megakaryopoiesis, relatively few direct transcriptional targets have been identified, limiting our understanding of the molecular mechanisms that regulate megakaryocyte differentiation and platelet production.

Objective: To identify direct transcriptional targets of ETV6 during megakaryocyte development, define how the ETV6 P214L mutation disrupts this regulatory network, and determine the contribution of these alterations to the pathogenesis of ETV6 associated thrombocytopenia.

Methods: Using CRISPR/Cas9 genome editing, we generated ETV6 knock out (KO), ETV6 P214L knock-in, and silent control variants in cord blood derived CD34+ hematopoietic stem cells (HSCs). Edited cells were differentiated into megakaryocytes over 14 days and evaluated for proplatelet formation and spreading. Multi-omic profiling included ATAC-seq to assess chromatin accessibility, CUT&RUN to map genome-wide ETV6 occupancy and bulk RNA-seq to characterize transcriptional changes across conditions. Differentially accessible regions (DARs) and differentially expressed genes (DEGs) were integrated with CUT&RUN binding sites to identify high-confidence direct ETV6 targets, which were further validated using platelet RNA-seq from individuals harboring the ETV6 P214L variant.

Results: ETV6 KO megakaryocytes exhibited impaired proplatelet formation and reduced spreading on fibrinogen, confirming that ETV6 is required for terminal megakaryocyte maturation. ATAC-seq demonstrated that ETV6 P214L megakaryocytes clustered closely with ETV6 KO megakaryocytes rather than silent controls, indicating that the P214L variant functions as a loss-of-function allele. Differential accessibility analysis identified 1,554 and 1,113 DARs in ETV6 KO and P214L megakaryocytes respectively, with 811 shared regions (44% overlap), demonstrating convergent chromatin remodeling. CUT&RUN revealed strong promoter-proximal ETV6 binding in WT and silent control megakaryocytes, that was nearly abolished in KO and P214L. ETS motifs were highly enriched within WT/silent control peaks (E = 4.6×10⁻³⁵⁶ and 5.1×10⁻³⁷³), but absent following ETV6 loss. Across WT and silent control replicates, 934 consensus ETV6 binding sites mapped to 701 direct ETV6 target genes. Bulk RNA-seq identified widespread transcriptional dysregulation with 287 upregulated and 218 downregulated genes in ETV6 KO, and 319 upregulated and 218 downregulated genes in ETV6 P214L megakaryocytes relative to controls. Gene ontology analysis of upregulated genes demonstrated significant enrichment for small GTPase-mediated signaling and actin cytoskeleton organization, implicating Rho GTPase dysregulation as a downstream consequence of ETV6 loss. Integrative analysis of CUT&RUN, ATAC-seq, and RNA-seq identified ARHGAP31, a GTPase-activating protein (GAP) for CDC42 and RAC1, as a direct ETV6 target. ETV6 was bound at the promoter region of ARHGAP31 in WT and silent control megakaryocytes, whereas binding was lost in both KO and P214L. Loss of ETV6 was accompanied by a 2.2-fold increase in chromatin accessibility at the ARHGAP31 locus and transcriptional de-repression (log₂FC = 2.4 in KO and 2.1 in P214L). Importantly, platelet RNA-seq from individuals carrying the ETV6 P214L variant independently confirmed ARHGAP31 upregulation (log₂FC = 2.9), directly validating our findings in patient-derived samples.

Conclusion: The ETV6 P214L mutation phenocopies complete ETV6 loss producing comparable defects in megakaryocyte maturation and genome wide transcriptional regulation. Integrative multi-omic analysis identifies ARHGAP31 as a direct transcriptional ETV6 target. As a GAP for CDC42 and Rac1, increased ARHGAP31 is predicted to disrupt small GTPase signaling required for cytoskeletal remodeling and proplatelet formation. These findings provide a plausible mechanistic basis for thrombocytopenia associated with germline ETV6 mutations and establish ARHGAP31 as a priority target for further functional studies.

Hyder Mir, PhD, Post Doctoral Research Associate: No relevant conflicts of interest to declare.